Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers

Rosebud O. Roberts, David S. Knopman, Jeremy A. Syrjanen, Jeremiah A. Aakre, Maria Vassilaki, Walter K. Kremers, Michelle M. Mielke, Mary M. Machulda, Jonathan Graff-Radford, Yonas E. Geda, Prashanthi Vemuri, Val Lowe, Clifford R. Jack, Ronald C. Petersen

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Objective: To estimate the prevalence of elevated brain amyloid and reduced cortical thickness (as a marker for neurodegeneration) in a defined population. Methods: Mayo Clinic Study of Aging participants underwent MRI to assess a composite Alzheimer disease (AD) signature cortical thickness measure and PET to assess brain amyloid accumulation. Participants were characterized as having elevated amyloid (A+/A-), reduced cortical thickness (N+/N-), and A+N+, A+N-, A-N+, or A-N-. The prevalence of AD biomarkers was derived by adjusting for nonparticipation and standardizing to the Olmsted County, Minnesota, population. Results: Among 1,646 participants without dementia (mean age 70.8 years; 53.2% men), the prevalence (95% confidence interval) of amyloidosis was 21.1% (19.1%-23.2%): women, 24.3%; men, 17.5%. The prevalence of reduced cortical thickness was 28.9% (26.4%-31.5%): women, 27.9%; men, 30.2%. The prevalence estimates of biomarker categories were as follows: A-N-: 61.4%; A+N-: 9.7%; A-N+: 17.4%; and A+N+: 11.5%, and varied by sex and by APOE ϵ4 carrier status. In men, prevalence estimates were as follows: A-N-: 62.6%; A+N-: 7.3%; A-N+: 19.9%; and A+N+: 10.2%. In women, prevalence estimates were as follows: A-N-: 60.4%; A+N-: 11.7%; A-N+: 15.3%; and A+N+: 12.6%. In ϵ4 carriers, prevalence estimates were as follows: A-N-: 54.6%; A+N-: 16.6%; A-N+: 12.4%; and A+N+: 16.4%. In non-ϵ4 carriers, prevalence estimates were as follows: A-N-: 63.3%; A+N-: 6.9%; A-N+: 19.9%; and A+N+: 10.0%. Conclusions: These prevalence estimates are important for understanding age-related trends in amyloid positivity and AD signature cortical thickness in the population, and for potentially projecting the future burden of biomarkers in elderly persons.

Original languageEnglish (US)
Pages (from-to)2039-2048
Number of pages10
JournalNeurology
Volume89
Issue number20
DOIs
StatePublished - 2017
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers'. Together they form a unique fingerprint.

Cite this